EDIT - Earnings call transcript Q4 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to Editas Medicine’s Fourth Quarter and Full Year 2017 Conference Call. [Operator Instructions] Please be advised, this call is being recorded at Editas’s request. I would now like to turn the call over to the Editas team. Please proceed.

Mark Mullikin

Good afternoon. Senior Finance Mullikin, at Investor Mark Medicine. Editas is Director and of Relations This fourth full quarter call. our to Welcome and year conference XXXX We XXXX earlier quarter release be covered the issued reviewing call. will a fourth this our Company, this which and and results afternoon year on updates regarding full press call be on website after completion. the two replay approximately & Media A hours will of Investors today’s our available section of its remarks, we will open for call prepared the Q&A. our After

this important factors, those the various the call from of most SEC. plans Factors Private reminder, As on provisions of in those remarks our including section results Act future forward-looking make during by XXXX. under Reform Risk the with materially is the that quarterly XX-Q, expectations, may statements which indicated Form about a various and statements we Company’s for report as file safe on the constitute prospects recent Litigation Actual forward-looking purposes discussed Securities of differ of these a result harbor

addition, our should statements as as any as upon subsequent only represent our of representing views forward-looking be relied and date. not today, of In any views

of obligation if date the statements While to some do in forward-looking disclaim any today. be update relied future, not should our our even to any as we subsequent representing statements we point so views views change. specifically forward-looking at these elect may These as upon to

Officer, our Executive to Now, over Katrine I will the turn Chief Bosley. call

Katrine Bosley

of Financial a Andrew today genomic members Chief ever Scientific Myer, joining Affairs. medicines patients. Technology pioneer our for Gerry than to for Corporate Senior Officer; President Editas for broad Officer; fourth year Vice Charlie the Officer; including XXXX. our Chief am of new Mark. our full our Medical everybody, is Thanks, Medicine Chief stronger you by Tim Hunt, our of our corporate positioned and our Chief quarter Good afternoon, Officer; several Cox, Hack, class call update Vic team, thank joined us executive Albright, and our for I

We preclinical major momentum package was Our team outline Today a accomplishments made as for tremendous in Editas. we our of will data progress XXXX in our number a substantial and recap well medicine EDIT-XXX. year advanced as capital progress, multiple towards goals into value-inflection robust XXXX added to a set with briefly carry goals unparalleled for ahead, lead that into XXXX. forward. of diseases. provides to and long-term our vision. and tumors through and for oncology create platform collaboration first solid Therapeutics; the Juno generated HPV-associated candidate medicine points. experimental year for We the our transformative with our eye develop an for medicines. tailwind to genomic We for regulatory deepened And translate course formed us XXXX foundation, Allergan talent manufacturing a strong These our medicines serious approximately We adding accomplishments $XXX alliance patients with million to we funding clinic. provide this

have to pipeline to to of broad focus genomic expect we of platform this goals beyond. EMXX our portfolio vision build These EMXX. built five editing And We will of in at our and our demonstrating five pipeline; eye either beyond; or XXXX a organization in manufacturing additional enable year programs this INDs continuing as leverage stage goals strategic XXXX, our into incorporating proof-of-concept engineered we cell five-year edited and developed. laboratories plan and out stage at for the translating Medicine our XXXX. be Editas programs; will we’ve further to date and ocular alliances in expand, and cells medicines, accelerate disease trials. technologies the see capabilities organizational they end Medicine’s This in include establishing on and excellence to will three by for at ready in our current platform to that possible our our new gene for for medicine and advances call for capabilities that patients. We’ve preclinical mid-XXXX; trial of underpinned transformative programs two with by in By T and These for least goals by continued success editing the amplify cultivating best-in-class differentiated exceptional pipeline and culture EDIT-XXX Our build least medicines experimental focus improve build a programs commitment goals late defined those additional for robust more a Editas be with where are and building advancing unmatched cancer, IND clinical the least on filing and Editas. end also medicines best-in-class and clinic, articulated where clinical successes, evidence we the on at to what’s culture. aim strategies CRISPR early additional our an deliver other both, of on in

Now, advance this plans over pipeline I’d discuss year. Chief the Scientific to our Albright our Charlie to Charlie? to like to our turn call Officer,

Charlie Albright

Thanks, Katrine.

our of about FDA ocular start excited I our on research of founding address work want at potential collaboration medicines. our programs before I the We’re this translational our discuss a the Editas. engineered CasX. The XXXX. with scientists cell question, radar immunogenicity to we But to formed of since immunogenicity year on in the in and with programs, been And ahead CasX for has

in of donors Genome pyogenes And we for we preexisting tested to this Symposia. collaborative and presented using quarter some these fourth Precision from assays for serum XXX at and in antibodies to work, the sensitive these As assays In humans preclinical Keystone recently, either human part of assays last Editing this the or we CasX shared antibodies aureus. specific data study, anti-CasX species. year. staphylococcus We more the detect developed of of streptococcus details

gives a had confidence antibodies of immunogenicity that either of look of of more sharing low to samples is issue conferences. being is the CasX. data be these of anti-CasX that still to this or estimate set medicines. the CRISPR-based the for data And XX% This medical While to development evaluated, continue of we species Editas we antibodies forward significant less area level at upcoming work in unlikely and

work the on academic that CRISPR on of continue invest medicines, types of immunogenicity Our the addressed example work exciting is research. in one editing to questions the we in the of to the these of be translational need and we CasX as translate types gene

ocular our pipeline. Moving onto

We LCAXX trials a are EDIT-XXX continue to IND for filing. towards and clinical mid-XXXX project advancing

to natural The year. we in report As approach filing, progressing we study history inform interventional trial design expect to data is the first conducting half a and facilitate of clinical enrollment. the initial our also study we’re and next

retinal first loss degeneration ocular Beyond talk pipeline that patients editing can our night USHXa be tunnel in is medicine inherited We’ll ever-narrowing present in vision leading the vision. diseases severely months. and adulthood, Ear We collaborators causes about results retinal potential our to approach future generated by a Eye over EDIT-XXX, then time and our that of loss gene eyes. retinal and develop broader to for experimental with or is infectious Massachusetts leveraged followed validate USHXa starting the with advances vision. from in with address of upcoming to how to diseases and diseases, Usher plan Xa medicines. inherited additional adolescence dystrophy emerging inherited of Starting impaired begins nicely Syndrome or medicines vision type photoreceptors, Progressive

entire AAVX medicine use we deliver an several will approach. subretinal As the the EDIT-XXX, to staphylococcus medicine example, our expect In CasX, of expect medicine for of we experimental USHXa aureus that particular, to features the LCAXX. machinery leverage the USHXa editing and for the delivery

this into neurons. of of infectious the cold corneal a infects neurons ocular replications Turning is often care Herpes reactivation sores, scarring this our eye that eye. cell advance by inflammatory cancer. corneal we affecting leading reduces or to are To engineered reactivation patients. to simplex rabbit programs commonly latent HSV-X cornea. HSV-X are a recognized keratitis, I’d keratitis. most medicines to latent the in cell gears can in and viral these encouraging The reactivation virus Juno to in current and Vision engineered of start the Therapeutics infectious treat approach genomes lead blindness. viral medicine, to a thereby in same meeting, target cause virus in for the late we’ll our reduce model leading developed need, Ophthalmology treatments episodes to we HSV-X to unmet ocular approach the many virus type where month, failed response and a CRISPR-based in diseases though virus X to next program. destructive continue this reactivation with And for reactivation a These collaboration latent show pool is as develop medical our Repeated sharing cause trigeminal Research keratitis, Switching proof-of-concept and cause At of scar. virus address there the ocular in the to block for Association standard blindness. vivo progress that like data in leads of T to and in

studies maximize papillomavirus identified cell that receptor. medicines Unfortunately, antigens function As to loss papillomavirus-associated cell molecules antigen the the Juno be associated or CARs medicine then cell T tumor Juno cell develop antigen T significantly receptors in year T Junior such intracellular are recognize an receptors, this antigens receptor the engineered recognize solid CARs. cell, T optimized clinic on needed T next chimeric both out year. majority introduced inside Editas To To To and including engineered endogenous begin the of cell and receptor. to cell scientists cell known the increased and tumors. of engineered this for antigens, surface. include engineered papillomavirus cell. chimeric cell as the CRISPR antigens T of receptor to instead of the of These T endogenous limited the engineered to T tumors, the use receptors existing to you knock receptor tumor are appreciate, antigens. to for IND-enabling receptors expression expects human expression tumor-specific aims tumor antigens scientists expressed scientists this a showed solid

engineered this tumors receptor in T outstanding engineered T the encouraged an of because been all cell advancing and are to receptors. of T for partner made medicines program, approach medicines We cancer. progress containing cell potential address applicability because as need by cell for strong by papillomavirus-induced to of unmet the Juno’s our the evidenced on both we’ve likely the knockouts

Some of pending wondering for implication may of you acquisition our about collaboration. Juno be Celgene’s the

we we working our believe to has potential newly which the Let oncology. combined T with are expand on for and the engineered further accelerate me cells company continue say, enthusiastic work

our with make T progress engineered disease cells, toward to patients on superior cell a progress addition continue sickle medicine and In we for to beta-thalassemia.

BCLXXA the and approaches gamma-globin increase latest In targeting integration. restore progress We’re edits plan to we genomic to erythroid fetal interrogating expression. beta-globin fetal the to edits adult novel first including increase durable for enhancer globin that pursuing are our and multiple in potent present gamma-globin, year. half others a the targeted by to expression differentiated excites We of contrast are more

turn review the Chief to our discuss I’ll Financial building the call financial results earlier how Hack are Now, today. and over to the reported Officer, business to Andrew we

Andrew Hack

Charlie. been certain of capabilities with for XXXX, will from has ocular advance and leader in valued a medicines. medicines, sustainable made year, making diseases. we medicines a RNA critical accelerate years. engaged in eye in pipeline partner CRISPR-based making its our Early building a to serious Then, iX providing a Thanks, medicines. the partner, affiliated Allergan strong iX of early guide Allergan tremendous in perspective for input companies ocular our and has that that for us We be has of collaboration we for progress high-quality particularly formed enabled and and been us we business number highly technology cell expand of engineered XXXX. as valuable assets and a portfolio Pharmaceuticals strategic acquired

discovered chemistries onboard. have technologies to RNA the also to Given felt together, we these our iX work acquire through importance was guide the assets valuable team related and it the of critical that bring we to

business and cutting-edge Each assets technology. genomic on to team of and of will what look towards relationships our leaders every establishing whether with right expand believe Colorado, RNA doing commitment transformative the well on of are we Boulder, we in our continuing do, so, improve and our to to define a integrating forward guide world in exemplifies we the and particular chemistry. area transactions accelerate, or medicines. these in We In pipeline aspect the therapeutic way

our roughly in financial fourth summarized XXXX Turning to the the we numbers, have release for quarter the results press an ago. we that made full-year hour and available

items equipment payments $XX million stock-based Our expenses of in million million and $XX.X non-cash to our recorded $X million. licensers cash on totaled charges totaled approximately R&D our XXXX Key capital spending approximately include associated depreciation. non-cash approximately with $X.X operating our million in compensation, of $XX of statement and income

size course these Over spending at platform. expanding our in expect pipeline drivers the spending the XXX end to in The in our of in XX by year, we drivers to of maturing of be from increasing grew the and employees organization of advances growth XXXX of continue And primary and we primary roughly growth XXXX. our were the XXXX. our full-time XX%,

As our further we XX, fund of cash have capital the we XXXX, therapeutic gross marketable and in the advancement leadership. and and $XXX underwritten position, deal approximately extend bond cash, programs to on equivalents of least to yearend believe multiple including December our proceeds of at Based months our technology XX had of parallel from million in we in [ph] $XX.X December. securities million cash

addition, in to under cash further back our strong selling full quarter, advantage ability available the our facility, our I’ll inflection In first with And the hand liquidity and it runway in value hand. million existing to extending of ATM our took that, points on with reach stock, critical $XX Katrine. we

Katrine Bosley

close like Andrew. of skills, of a to extended range Editas you, tremendous by team. a and And Editas I’d talents members Building Thank new capabilities. our welcoming Company several takes like

who our and Directors Board Editas First, welcome Hopfield, joined welcome and great to Jessica business the and just to expertise brings to Boulder. scientific second, table; of

our are the an excited commitment unparalleled brings critical that to noted, we And from leadership we our continued closed is new Pharmaceuticals in and only editing acquisition. Andrew Boulder, earlier the members chemistry RNA assets Editas, announced to As very talented it genome in year. acquisition welcome This And Colorado. team have first of iX exemplifies not it capabilities platform. to out our build also we

with support. open always, you And and for all to we we of that, thank up As your will it interest Operator? Q&A.

Operator

from question [Operator comes Gena Wang Instructions] from Barclays. Our first

now is open. Your line

Unidentified Analyst

This is Parag [ph] on for Gena.

couple, potential deliveries -- of development share just that? cell the any quick the secondly then, some you you space, on a wondering on autologous Is Just one views specifically competitive regarding therapies? gene of Usher the wondering, Juno And about first nanoparticle Could provide collaboration. you questions, part the differentiation competition how against two therapy this Syndrome, collaboration? if might your and therapy your could think color using

Katrine Bosley

Sure.

our approaches bit little talk And Vic about little collaboration. Myer, I’ll about and our let the Chief So, others to to Medical Gerry me first then, Cox, bit Juno ask ask Technology Officer, have. may different Officer, that Vic? a Chief a talk USHXa

Vic Myer

Yes.

we excited Celgene. merger after So, with really Therapeutics remain with about the work Juno our

work continue strategy. scientific We very to closely on

have insertion We disclosed in allogeneic rates the edits multiple T haven’t ability perform disclosed cells. program to-date, T but targeted and of we yet an in high cells to

Gerry Cox

conventional terms not In the vector. of within It’s packaged is AEV USHXa be USHXa very a large program, a gene. to able

approaches. Our replacement type editing approach advantages us believe we size-agnostic, other using over which genome gives is

Operator

next our Stanley. comes with And Morgan question Harrison you. Thank from Matthew

line now open. is Your

Unidentified Analyst

is, need and first you size eye Matthew. talk in the is recurrent think This [ph] you progress the My how the now you for Ishmael quickly infection can for right opportunity can do question of on about into the clinic? indication, the the and HSV unmet and Hey.

Katrine Bosley

just that to timelines haven’t to So, I to make updated With progress. we regards people obviously look disclosed specific speak the keeping we’ll we clinic, yet. on will Gerry advancing to question. the Gerry? forward patient to ask as size, But,

Gerry Cox

Sure.

year, XX,XXX It’s to we herpes cornea. there of the X,XXX cases is eye. which an and repeated about lead is to keratitis, these, which So, reactivation of the blindness. reported. ocular herpes, bouts disease are cause the common keratitis, of of in called about can most the due virus blindness stroma, is infection Of infectious to scarring corneal referring the actually Each stromal called

Unidentified Analyst

So, just two more for me.

give more strategy And demonstrated the the in T oncology speak to already question in you could you For still to you’ve the And would in before models. about in but year? sickle of are talk have into you cell, can rates editing arrangement And I cell What expect can clinic? your you oncology? be platform other in about some first be, half of to progress you you you high taste the what of therapy, able looking you the leverage a do report broadly? us of could engineered my second how know preclinical

Katrine Bosley

Sure.

would Charlie, with So, you cell regard disease, like address question the to to sickle please?

Charlie Albright

Sure.

product, of a in induce or lead fetal and that that reproducible be with one sickle in aim Our either to beta-globin a BCLXXA would differentiated re-expression to more disease approaches. currently and is lentiviral-based current develop way possible and robust than with and hemoglobin more the more enhancer, real cell the broadly approaches that’s would

to So, medicine. And those those at we entering are gating determine give most approaches which this experiments the is point will going be of us differentiated trying for clinic. to the

Katrine Bosley

a been on has particularly are that touch your mature, called historically are we’ve a significantly bit regard is cell genome bit or have a And about range one strategy, the in between those how to begun lines editing broader little gene of to blurring what to particular with then, some truly cell -- therapy. And products as the question therapy. of really it achievable, talked expands our therapy of things on the actually might

medicines view that we the makes So, that expanding possible. cell-based because opportunity as universe of in expansion editing

types, something So, with with with set linchpin months makes initial cell-based about many you’ll fact possible that’s achieved is frankly engineered oncology/ well I editing. wide medicines, that for products in and there’s variety coming Celgene us. excellent hear now be certainly could cells relationship been more But, T more our without an editing the engineered cell than Juno, us opportunity CARs as of think there over the And and T cells is as and to Clearly, talking a it that’s years. regard that --

Unidentified Analyst

to guys be a Would of will looking you that into? particular area go be there oncology

Katrine Bosley

far opportunities as the oncology extend think beyond I well.

Operator

Thank you.

Our next SunTrust Robinson. with question Peter from comes Lawson

Your line is now open.

Peter Lawson

Thanks the for the update EMXX. for

as of mean, about disease stay technology we and think how thinking we disease that kind Just broad should number you kind number about of got maybe kind through? verticals of and really that of of I verticals, you’ve a how of think we’re focused period should over time?

Katrine Bosley

we opportunity a as that, It’s Yes. been Clearly, excellent No, areas that This a to kind wrestle developing established benefit to is from you biological and to talked ocular two applicable thing expertise platform. Allergan here. when one, with brings regard greatly have broadly exactly we question. we we’re great that quite the the about the disease. one that there. bit the with has And table have it’s actually a clinical of

has we that. -- So all of from leverage lot internally. build don’t that We of expertise to that have get a

our But, there’s continue is lot vivo, oncology we’ve programs. cells cell Juno with with T work So area also business the within Allergan that Celgene a commitment the where long-term exemplary you area development us a commitment relationships wholly it in a noted, engineered an have be engineered is oncology. work owned is we build relationship technical that do well we strategy a through Clearly, area. because that it we it ex in really the of our of leverage beyond in the done, in have we from with certainly all expert if an as where get but and the We have, deep helps faster -- our even do where accelerate both more as to area had and already lot in and in can would second on medicines, own. we’ve than in will in

themselves, pursue of some partners. will with those And some of those we

that continue right But, a because And in finding our on do on question part partnership. depend expect us will think, faster. partnerships programs for the see stressful any partners. balance will the really own where that I to us time. sometimes develop kinds we with and both, enable to to expand go will of develop right over That’s -- for we

Peter Lawson

of data of of data number of on, or we XX to be that be for of Thank need about patients the the you. what release would helpful. And release Thank the then, Anything And next you. you you’d would over tens? ends really kind kind venue the ones, should ends think of months? you it think around

Katrine Bosley

that So, to is to mid IND said, by data to an given of to with will a with regards study release. ask what what this done trial we the goal regards little not like. Gerry look have the year. we anticipated as clinical design bit X/X think LCAXX Phase program, our schedule the I’ll But, talk and is just file we

premature design, I study think talk data But, Gerry? about it’s terms to a the in little release. of

Gerry Cox

Sure.

dose out a Phase will enrolling in levels the early patients there. treating expanding or in So, into half. X/X the study study. be We be this preliminary study initially administered reporting year, patients. design be pediatric in to next natural We’ll human be will doses we’ll increasing history data which cohorts the of small The escalation first from then are of and adults year first

we we’ll As dosing decisions different and making a cohort, safety of through efficacy, next both enrolling be progress patients. additional the assessing about cohorts, and

to in that will study. time in Right a between So, now, XX planned enrollment. throughout patients the be and XX it’s real study one-year the occur

Peter Lawson

that could Would you you’ve be history think think Phase patients identified how do the sites the we the you should X? study, roll kind of For it many about? natural mostly to in

Gerry Cox

So, history Europe the taking both sites. place and the in U.S. study natural is at multiple

enroll to XX We are to planning patients. up

obviously say in premature interested patients be X/X right be from enrolling. what it’d probably would patients be And number those of study some study. Phase would of the to But that enrolling now

Peter Lawson

where of give question final headed? just update then, the an that collaboration, And could and just on Adverum it’s Katrine, one you kind us

Katrine Bosley

Adverum some done because with would interesting product, intriguing by as but some for year vectors they’ve there. they’ve we product established as with is encouraged fact potential over work continue driven that little very And product. So, to EDIT-XXX defined, innovative that be our And ophthalmology. for there. would done ago already our updated future we That a to in and largely a what that see we is share be now, regards keep the a novel at it there very work we think data by relationship a had that meeting. We’ll medical we would not you be configuration have I

Operator

from Company. And Nadeau with Phil & Cowen our comes question next

now line open. is Your

Phil Nadeau

first would the on the other Juno to by the two testing of time stage right guidance, TCR. most programs testing in or few stage that guidance It that potentially near long-term the EDIT-XXX Couple, there having or in programs and be seems late-stage program be within late make Am at like XXXX. it I years? thinking late to are could testing about also that that a programs likely

Katrine Bosley

Yes.

later the think you now. have right the most the ones ones the going that stage will that to visibility I be in be programs are that’s sense on the

you So, can clinic. to And time or on are the that to programs IND, as potentially two in line it’s able particular timeline. see that the the certainly defined be late what more to next the as in in early year be constellation will programs stage a programs clearly of additional be

right and timeframe? cell ocular the will And advance is and think it work so, the that in about that engineer you work what T way

Phil Nadeau

second then, development. business on And

new deals years last elements of platform. done to You the the few the into that mentioned bring to into you’ve bring a the platform recently done couple or new elements over

complementary the be at to your you what now, to fill If the are platform technologies you useful else what would need, abilities? were think out look do you

Katrine Bosley

something to But, Officer, our talk Vic over as that. going know, I’m Myer, it’s one Chief continues ask Technology where to to you to look also time. So,

platform I in scientific always world. today. evolving think are looking But, you have that the an at we excellent how are things

Vic Myer

Yes.

in analytics we We we in is first around CpfX quarter can in we year of the recap, now, over sort really engineering feel So, for are world-class us. think -- that additional nuclease bolster first did to things frankly, that maybe space. brought the But guide. well-suited half right and continue look half to in a a help We we and chemistry all ago, for brought what like that year. the this and so technologies of into

around targeted additional a in some exploration do gene insertion cells We’ve and external us. primary to also reported really not So, it’s huge of area nice able work for being correction.

so, we huge not they But, a And of place again, so area to that’s continue new a technologies, out. investigate come where it’s investment.

think an energy looking time do is we or spend by going lot to formats. a tissue do increasing We and based alternative I ultimately of is think the a delivery opportunity. that of at time where place disease amount disease delivery and be energy tissue and by

And they therapeutic delivery so, we’re always the exploring potentially technologies actively current to new and areas our ones. as apply new

Phil Nadeau

of developments of last between just When your one on might then, hear What interference question there? And we the the that next University any steps California, and collaborators. academic are dispute? of out

Katrine Bosley

Sure.

would not likely patent it past number of in the recalls, other scheduled, for goes process disclosed which appeal in been the and and everybody was anticipate domain. there a hearing be is of step oral through few when appealed So, That And States. last Court. sure will replies issued that February that have division, an U.S. we’re there well. is fact is yet we their that a as Circuit occurred all And over parties next in publicly as the of by decision that the upholding motions favor United in the And a issued public the to Broad’s year, Patent scheduled, in Office has Federal months QX. but very be that favorable of

Court, requirement Federal there we deadline to wait look decision. not like is and We take. that, subsequent a So, see It’s not of just from how explicit at is then will to long be will an decide. have But, timeframe Circuit can think, what the hearing. decision is. they for when typically that of they I there there And the a that statutory conventions

Operator

Securities. question next comes our Mike And King JMP from

now is open. line Your

Mike King

where to up maybe line start I Phil’s a wanted off going. of bit was questioning picking

understand of Just help us on view on certain editing. about you help you don’t look labs guide sit and the of scenes. guys Editas’s greater the things f I you working open at us, But, versus How get an that where get at look you going what’s could like is publication the in see sort or you talked sort makes specificity lots technology the wondering could recent wondered world? strand that improvement what to can headlines. outside of you lots just know of innovation really many space source things if of so behind are what from gene I because PAM CRISPR do where new that investors as approach where the published

Katrine Bosley

that talk Vic particularly a I’ll But, let to of bit to the with PAM framing this. regard Sure. question. ask offer little to me to

that gosh, interpret immunogenicity has challenging to an of questions a are great does say, in assessment First little things a us cause this because appreciate this be anybody is to that everyday of posted A people epidemic mean? bit was it there that to that anytime on of so this, give January and we can paper year oh, an on some example lot completely intense in was is what archive my the this would bio there call. early much that live this make issue… Because headlines focus world sometimes we a be field all, it

Mike King

you that about to going ask next. was I

Katrine Bosley

address that with the Sure, and the it already an on reasons it was FDA a that’s working manner. wanted we we’ve collaborator felt been like question one very a year half a to because at rigorous we And absolutely. important -- for of and a

that’s the are the So, into of to a of examples kinds little that work on that that specificities I’ll kind young academic kind can companies more. we’re making to really we fundamental often course bit science is medicines; Charlie move academic not these speak stuff science science we’ve But, of why and of here. translational ask other that. That’s the questions made tremendous of that purview science. do, ones It progress. lot are translational A of where great --

on number capabilities. there We’re front very that aspects. confident of other are our a And and

other and lot immunogenicity, like that things maybe attention like very of question et get think and fronts. be I are case will confident cetera, -- help on at science a and in we that of specificity, the those wouldn’t So, appreciate headlines interpret pharmacology, all we for translational a each working you. the the on that fields, of can are like we those level of But, the

perhaps getting if level So, science do. of PAM to that want of about talk the sorts Do bit elements unique field, something you is attention this that is to the of the a they those question?

Vic Myer

sure. Yes,

of you on cut certainly we up to a take it’s them course nice referring with literature. And cognizant published they innovations Liu’s of as were and at David keep So, work all I PAM the actually at to piece would up PAM things capabilities, we’re genome. always always year the and and the recent us add and allows the happen one their already of the lab look human a of these when outside. a is over ago we family great of about of a the base entirety every that at we say, almost it CpfX variance in-licensed recognition in

large within reducing genome. and by targeting us is target the the the the a of we’ve diverse that can of very problem gives way suite size bringing flexibility enzymes human So, of in that a portfolio of so we practice, that tackled

sort that And see opportunity. is into that’s on as lot of we’ve working great and it’s energy CRISPR. us, actually minds advancing how going platform. of of ton a addressed are that that There great brilliant So people a further for think we the Overall, question. we there

Katrine Bosley

add Charlie, and some like with regard And what you views questions, on done to repricing, the our would immunogenicity to just we’ve that? kind comments of

Charlie Albright

Sure.

been earlier, this every how on into a are types time developed going that I on and such of is proteins these to some mentioned therapeutics. or there biologic as mentioned you’re antibodies time. assays And And for human. novel assays so, guidance well-established as to put as use develop working we’ve And a quite

antibodies. we the and of So, are therapies, of we for in you intracellular, gone see before to vivo therapies preexisting use the the ocular if impact don’t preclinical new and that at humans And it’s human, guidance machinery don’t CasX induce and eventually us allow this would be. back And antibodies. expect in expect will induced in develop paradigm a antibodies, assays. our ex the to Certainly look editing case and will, CasX be in the them antibodies case we we to unclear of in high rate those the therapies, proteins of long to at species. go the point, our what proteins preexisting It those

Mike King

Charlie, is the that work? there expected would be seen to have antibody of to Proteous that paper [ph] in point something might specific in you you level a higher induce reaction your than guys

Charlie Albright

the assays drawn. or is main the to the difference two between were that that think, come the of were to used pieces conclusions work I

assay measure a to you blotting used the that small. western without And so, bio-archive if control specificity were number of the preexisting And of adjust was the as were to level furthermore, at the look paper, antibodies. humans tested competing

test first validated, obviously very paper. in XXX of And a that would, conclusion sensitive we samples numerical validate come tested assay developed we a and to specific so, as new working set we And on on different that was then thought that was that and it to XX we a samples. then

Katrine Bosley

it’s the They assume part this oftentimes, kind one the And but we when what of way, importance glad thing we medicines. opportunity whether in in important funny, folks you, raised, odd talk do these sort happening. it’s or just are immunogenicity gives get an these it because I of interested an specificity work, a of aren’t are because questions about of things it. add, -- actually all And kind actually or really developing of have to us might

important And Charlie work, the can doing. hopefully regulators nice way a the would to are and Vic actually expect. we FDA of where And you you met a that team are of lot get how requirements us about have it, it’s so, and this we it’s do opportunity that translational more into talk and for in the insight other kinds the

Mike King

color kind of enthusiasm just if through smoothly need Great. might even Juno along your I going required a on strategic natural it’s on that. your wonder to here. lookout review formal there’s that’s company near-term prior it’s collaboration. to to the you additional your just for for and I go candor closing also maybe the be anything to to continue on that in that or know, expressed upon for aware But, appreciate Juno follow-up question for remarks relationship, I And the impact closing. expectations. one in move of we And your the then, if you some

Katrine Bosley

relationship recall Juno Juno the and had on Well, a acquisition, such. well-established board that Celgene before seat long and a including for example

they relationship that relationship our -- with window years three established this and them doing, good ago. because almost so, And into Juno including with long had all of obviously is Juno our we relationship the a work

T a and see we editing that T So, long antigen direction good a they take. both with really time of putting could -- ago CAR to and together cells was these editing sorts the

for Celgene we’ve Juno. that some And at their this time see obviously through relationship So, them. could been with and with

for that the a picture think we that And think building so, Obviously, relationship company into confidence they’ve relationship strength comes It’s important great of our to with for clear folks have Juno the work they Editas been want of our I a Celgene great vision that long obviously where fits time into way a they’re how go this. Juno with and a a known able already. have from they time, are they and real window myself I’ve think bigger doing. the to long that I

Operator

comes Cory from Kasimov Morgan. J.P. with question Next

Your line open. now is

Unidentified Analyst

Matthew just and and specific presented, curious back any among immunogenicity go able associated to if you the been the enzymes, of Hey. the if immunogenetic to to And identify for regions thanks on for these real CasX either taking This nucleases? Cory. epitopes wanted is I CRISPR are quick. you’ve conserved my I’m questions. data

Katrine Bosley

we still on at what with Are of anything sort there want location, couple this chance remote it so any a his in on about give he me mentioned next we’re to bit be let are? the is But, to little Charlie, are or comments. steps the is So, more that, -- a line? prepared antibody you the assessment, the work it’s in steps. a immunogenicity in overall briefly checking you While just do one where Charlie. so, talk of CasX else, any and of or some Actually, Charlie

second immune question So, one or any all the that does low identify is we’re frequently, with. And find it is response. Then, -- can quite actually you begin of levels, even even mean is, you preexisting to and detecting anything? kind immunogenicity what

number were follow you it’s I very where that be this medicines. go. able going ways CRISPR-based making immunogenicity a is some And is patients. anything. then levels of so, Charlie, next And question That’s it we have for not to are But, on is would confident to in that you if we’re do those with percentage we of engaged small of even in when to thought have puts be such up if because sit But, position be actually do to work see for the consequence. we issue begin we’ll it we with, any mean And back a where significant today, asked level online? you think, we any of where feel there that get and in. Look, direction very, we’re low very there were a low also think we the those if position was meaning, can question we potential important even managed. very start that a important any only that to

Charlie Albright

Yes, I got back online, apologies.

interesting But, it I back So, had an like I missed getting trouble discussion. sounded on.

Katrine Bosley

to I that and it’s steps the So, our to follow work think are immunogenicity, of. what a the up just next in regard middle question we’re with on

Charlie Albright

Yes.

expand And so, we will we on will continue and the sample preclinical at size model. look response to our the

of even seen we have. for into we’ve induction there primates of had animals was humans the So, us And in But no safety the the work probably we built clinical look. primates, of to datasets non-human preexisting trials. place date in look editing obviously our non-human antibodies, we’ll on that which what for or and we efficacy the effect that to I assays in some the enter as either relevant small antibodies are that most

Unidentified Analyst

one step? thoughts And question relative cellular gene just curious the approaches current manufacturing program. on on to cell your therapy to have then, for include adapt a I editing ease I’m autologous or difficulty your

Katrine Bosley

talk that Vic, could you to question?

Vic Myer

Yes.

we that large to autologous for say our don’t it today. but in operations process it therapy cell as cell see disclosed it suffice the change haven’t stands unit manufacturing we as a So,

Operator

from Youngrin [Operator with Instructions] Our Kim comes next question CLSA.

Your is now open. line

Youngrin Kim

on one in I question the that deal had recent field. just happened

technology on it supposed treatment. finger to wonder deal cancer landed gene makes superior But, a choices zinc Sciences why Sangamo such on CRISPR So, made with be when editing to is me nucleases. Gilead Gilead

So, I comments some could that. if guys just get wondering I on was from you

Katrine Bosley

the others, relationship We given with our ago not we available with Juno. Juno three very to been scope for has established partner us and years with productive we important that relationship Therapeutics clearly have relationship that of were

can But, we might have and committed to others excellent they choices with they already were progress might of You we course making made. the -- Juno. made why have ask

is vision I had in their think reflect really days the about they’ve from it does the where field a on going. as very early company

have been long for we a lot of stuff a them working So, time. with together on

Youngrin Kim

could technology is it Just nuclease to a treatment? I��m Therapeutics a their to here CRISPR trying on cancer was went on I time a follow from up with than finger I zinc that, finger bet get where creating what guess be was thought Editas function have understand maturity that for longer zinc they so partnership. Gilead’s CRISPR perspective, would they of nuclease not Because on safer But going available. so, and is with of

made they So, why on I’m on what to just thoughts that trying get color some decision. are your

Katrine Bosley

we for T we not demonstrated we helped have We’ve And have done choices have I talk published we done From to of together. they why sorts may of through cells a that and should together with oncology that T CAR Ts editing such. -- have you the with improve the Juno. Yes. believed perspective, mean, expand have have with what’s I the and think always everything we all published really that work cells they lot our made made. about and them antigen possible, obviously,

excited continuing to excited be to So, there we that And for to now lot are about. very tuned are with Celgene. is Juno, a work stay we there

Operator

in Katrine I’m Bosley. over at to to call like CEO, questions Thank back queue turn you. no And the showing further I’d the time. this

Katrine Bosley

work that, And to in call, as evening. bring patients. thanks Thank as we transformative to to for participating Have as with today’s great support you for much. well a everybody so your Thanks. new medicines

Operator

call This you concludes may a Ladies and Everyone gentlemen, once disconnect. the your day. is great this more. operator all have and

Editas Medicine (EDIT) 9 Mar 182017 Q4 Earnings call transcript